Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

RecruitingOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

March 19, 2027

Study Completion Date

March 19, 2027

Conditions
CardiomyopathiesGenetic PredispositionCardiomyopathy, Primary
Interventions
DIAGNOSTIC_TEST

Plasma biomarker levels

"This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines."

Trial Locations (1)

G51 4TF

RECRUITING

Queen Elizabeth University Hospital, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

collaborator

Roche Diagnostics GmbH

INDUSTRY

lead

NHS Greater Glasgow and Clyde

OTHER